But in non-GCB-DLBCL, especially in rituximab-resistant non-GCB-DLBCL, whether BTKis could improve apoptosis through down-regulating NFκB activation and the underlying mechanism remain unclear. Here, NFKB1 is linked to diffuse large B-cell lymphoma.